GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innoviva Inc (NAS:INVA) » Definitions » Cyclically Adjusted PS Ratio

INVA (Innoviva) Cyclically Adjusted PS Ratio : 5.82 (As of May. 27, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Innoviva Cyclically Adjusted PS Ratio?

As of today (2025-05-27), Innoviva's current share price is $19.15. Innoviva's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $3.29. Innoviva's Cyclically Adjusted PS Ratio for today is 5.82.

The historical rank and industry rank for Innoviva's Cyclically Adjusted PS Ratio or its related term are showing as below:

INVA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.97   Med: 12.99   Max: 69.18
Current: 5.77

During the past years, Innoviva's highest Cyclically Adjusted PS Ratio was 69.18. The lowest was 4.97. And the median was 12.99.

INVA's Cyclically Adjusted PS Ratio is ranked worse than
53.11% of 499 companies
in the Biotechnology industry
Industry Median: 5.33 vs INVA: 5.77

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Innoviva's adjusted revenue per share data for the three months ended in Mar. 2025 was $1.413. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $3.29 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Innoviva Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Innoviva's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innoviva Cyclically Adjusted PS Ratio Chart

Innoviva Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.45 10.34 6.27 6.25 5.58

Innoviva Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.63 5.69 6.37 5.58 5.52

Competitive Comparison of Innoviva's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Innoviva's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innoviva's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innoviva's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Innoviva's Cyclically Adjusted PS Ratio falls into.


;
;

Innoviva Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Innoviva's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=19.15/3.29
=5.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innoviva's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Innoviva's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.413/134.9266*134.9266
=1.413

Current CPI (Mar. 2025) = 134.9266.

Innoviva Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.092 100.684 0.123
201509 0.117 100.392 0.157
201512 0.198 99.792 0.268
201603 0.214 100.470 0.287
201606 0.261 101.688 0.346
201609 0.273 101.861 0.362
201612 0.276 101.863 0.366
201703 0.336 102.862 0.441
201706 0.486 103.349 0.634
201709 0.406 104.136 0.526
201712 0.584 104.011 0.758
201803 0.461 105.290 0.591
201806 0.592 106.317 0.751
201809 0.544 106.507 0.689
201812 0.705 105.998 0.897
201903 0.487 107.251 0.613
201906 0.565 108.070 0.705
201909 0.580 108.329 0.722
201912 0.670 108.420 0.834
202003 0.693 108.902 0.859
202006 0.695 108.767 0.862
202009 0.781 109.815 0.960
202012 0.797 109.897 0.979
202103 0.753 111.754 0.909
202106 1.002 114.631 1.179
202109 1.198 115.734 1.397
202112 1.319 117.630 1.513
202203 0.961 121.301 1.069
202206 1.131 125.017 1.221
202209 0.702 125.227 0.756
202212 0.687 125.222 0.740
202303 0.851 127.348 0.902
202306 1.237 128.729 1.297
202309 0.781 129.860 0.811
202312 1.010 129.419 1.053
202403 0.917 131.776 0.939
202406 1.598 132.554 1.627
202409 1.422 133.029 1.442
202412 0.853 133.157 0.864
202503 1.413 134.927 1.413

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Innoviva  (NAS:INVA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Innoviva Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Innoviva's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Innoviva Business Description

Industry
Traded in Other Exchanges
Address
1350 Old Bayshore Highway, Suite 400, Burlingame, CA, USA, 94010
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Executives
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Marianne Zhen officer: Chief Accounting Officer C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Stephen Basso officer: Chief Financial Officer C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Margaret Koziel officer: Chief Medical Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Deborah Birx director 3300 LOWELL STREET NW, WASHINGTON DC 20008
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Pavel Raifeld officer: Chief Executive Officer 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Sapna Srivastava director C/O MYOS CORPORATION, 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Larry G. Edwards officer: CEO of La Jolla Pharmaceutical C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511